The University of Chicago Header Logo

Connection

Stephen Kent to Antibodies, Viral

Back to Details
This is a "connection" page, showing publications Stephen Kent has written about Antibodies, Viral.
Stephen Kent
Connection Strength
6.488
Antibodies, Viral
  1. Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure. EBioMedicine. 2021 Aug; 70:103518.
    View in: PubMed
    Score: 0.606
  2. The protective potential of Fc-mediated antibody functions against influenza virus and other viral pathogens. Immunol Cell Biol. 2020 04; 98(4):253-263.
    View in: PubMed
    Score: 0.546
  3. Antibody-Dependent Cellular Cytotoxicity Responses to Seasonal Influenza Vaccination in Older Adults. J Infect Dis. 2017 12 27; 217(1):12-23.
    View in: PubMed
    Score: 0.472
  4. Antibody-dependent phagocytosis (ADP) responses following trivalent inactivated influenza vaccination of younger and older adults. Vaccine. 2017 11 07; 35(47):6451-6458.
    View in: PubMed
    Score: 0.465
  5. Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine. J Virol. 2016 06 15; 90(12):5724-5734.
    View in: PubMed
    Score: 0.423
  6. Influenza-Specific Antibody-Dependent Phagocytosis. PLoS One. 2016; 11(4):e0154461.
    View in: PubMed
    Score: 0.420
  7. What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. EBioMedicine. 2016 Jun; 8:277-290.
    View in: PubMed
    Score: 0.420
  8. Genetic markers of enhanced functional antibody responses to COVID-19 vaccination. Vaccine. 2025 Aug 13; 61:127379.
    View in: PubMed
    Score: 0.198
  9. Randomized trial of same- versus opposite-arm coadministration of inactivated influenza and SARS-CoV-2 mRNA vaccines. JCI Insight. 2025 Jan 09; 10(4).
    View in: PubMed
    Score: 0.192
  10. Immune imprinting in early life shapes cross-reactivity to influenza B virus haemagglutinin. Nat Microbiol. 2024 Aug; 9(8):2073-2083.
    View in: PubMed
    Score: 0.185
  11. Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine. ACS Nano. 2022 08 23; 16(8):11769-11780.
    View in: PubMed
    Score: 0.161
  12. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine. 2021 Dec; 74:103729.
    View in: PubMed
    Score: 0.155
  13. Poor protective potential of influenza nucleoprotein antibodies despite wide prevalence. Immunol Cell Biol. 2022 01; 100(1):49-60.
    View in: PubMed
    Score: 0.154
  14. Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians. Proc Natl Acad Sci U S A. 2021 10 12; 118(41).
    View in: PubMed
    Score: 0.153
  15. Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight. 2021 08 23; 6(16).
    View in: PubMed
    Score: 0.152
  16. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. Proc Natl Acad Sci U S A. 2021 05 11; 118(19).
    View in: PubMed
    Score: 0.149
  17. Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nat Commun. 2021 04 01; 12(1):2037.
    View in: PubMed
    Score: 0.148
  18. Hemagglutinin Functionalized Liposomal Vaccines Enhance Germinal Center and Follicular Helper T Cell Immunity. Adv Healthc Mater. 2021 05; 10(10):e2002142.
    View in: PubMed
    Score: 0.147
  19. Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults. Vaccine. 2020 02 28; 38(10):2368-2377.
    View in: PubMed
    Score: 0.136
  20. A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface. Cell. 2019 05 16; 177(5):1136-1152.e18.
    View in: PubMed
    Score: 0.130
  21. Anti-Influenza Hyperimmune Immunoglobulin Enhances Fc-Functional Antibody Immunity During Human Influenza Infection. J Infect Dis. 2018 09 22; 218(9):1383-1393.
    View in: PubMed
    Score: 0.124
  22. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Nat Commun. 2018 07 10; 9(1):2669.
    View in: PubMed
    Score: 0.122
  23. Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection. EBioMedicine. 2017 May; 19:119-127.
    View in: PubMed
    Score: 0.112
  24. Dimeric Fc?R Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG. J Immunol. 2016 08 15; 197(4):1507-16.
    View in: PubMed
    Score: 0.106
  25. Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial. J Infect Dis. 2025 Dec 20; 232(6):1319-1329.
    View in: PubMed
    Score: 0.051
  26. Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling nanoparticles. Vaccine. 2025 02 06; 46:126668.
    View in: PubMed
    Score: 0.048
  27. Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster. EBioMedicine. 2023 Dec; 98:104878.
    View in: PubMed
    Score: 0.044
  28. Broad spectrum SARS-CoV-2-specific immunity in hospitalized First Nations peoples recovering from COVID-19. Immunol Cell Biol. 2023 Nov-Dec; 101(10):964-974.
    View in: PubMed
    Score: 0.044
  29. Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities. Nat Immunol. 2023 06; 24(6):966-978.
    View in: PubMed
    Score: 0.043
  30. Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine. EBioMedicine. 2023 Jun; 92:104574.
    View in: PubMed
    Score: 0.043
  31. SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses. Immunity. 2023 04 11; 56(4):879-892.e4.
    View in: PubMed
    Score: 0.042
  32. Engineered Ferritin Nanoparticle Vaccines Enable Rapid Screening of Antibody Functionalization to Boost Immune Responses. Adv Healthc Mater. 2023 07; 12(17):e2202595.
    View in: PubMed
    Score: 0.042
  33. Immunization with inactivated whole virus particle influenza virus vaccines improves the humoral response landscape in cynomolgus macaques. PLoS Pathog. 2022 10; 18(10):e1010891.
    View in: PubMed
    Score: 0.041
  34. Current and future nanoparticle vaccines for COVID-19. EBioMedicine. 2021 Dec; 74:103699.
    View in: PubMed
    Score: 0.039
  35. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain. Cell Rep. 2021 10 12; 37(2):109822.
    View in: PubMed
    Score: 0.038
  36. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Rep Med. 2021 03 16; 2(3):100208.
    View in: PubMed
    Score: 0.037
  37. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020 10; 5(10):1185-1191.
    View in: PubMed
    Score: 0.036
  38. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020 09; 26(9):1428-1434.
    View in: PubMed
    Score: 0.035
  39. Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. Sci Transl Med. 2018 02 14; 10(428).
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.